[go: up one dir, main page]

MX2018012392A - Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. - Google Patents

Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.

Info

Publication number
MX2018012392A
MX2018012392A MX2018012392A MX2018012392A MX2018012392A MX 2018012392 A MX2018012392 A MX 2018012392A MX 2018012392 A MX2018012392 A MX 2018012392A MX 2018012392 A MX2018012392 A MX 2018012392A MX 2018012392 A MX2018012392 A MX 2018012392A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
bchl
bacteriochlorophyll derivative
combinational therapies
Prior art date
Application number
MX2018012392A
Other languages
English (en)
Other versions
MX390751B (es
Inventor
Scherz Avigdor
Salomon Yoram
Agemy Liiach
Hamri Rachel
Preise Dina
Kim Kwanghee
Coleman Jonathan
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of MX2018012392A publication Critical patent/MX2018012392A/es
Publication of MX390751B publication Critical patent/MX390751B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un agente anti-células supresoras derivadas del linaje mieloide ("agente anti-MDSC") y un derivado de bacterioclorofila (de aquí en lo sucesivo en la presente solicitud "Bchl-D) para ser utilizados en terapia de combinación para cáncer, en donde el agente anti-MDSC y el Bchl-D se administran en forma secuencial y la administración de Bchl-D es seguida por terapia fotodinámica (PDT) o PDT dirigida vascular (VTP).
MX2018012392A 2016-04-10 2017-04-10 Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila. MX390751B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662320549P 2016-04-10 2016-04-10
PCT/IL2017/050440 WO2017179053A1 (en) 2016-04-10 2017-04-10 Combinational therapies for treatment of cancer comprising a bacteriochlorophyll derivative

Publications (2)

Publication Number Publication Date
MX2018012392A true MX2018012392A (es) 2019-08-21
MX390751B MX390751B (es) 2025-03-21

Family

ID=58794130

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018012392A MX390751B (es) 2016-04-10 2017-04-10 Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
MX2022003190A MX2022003190A (es) 2016-04-10 2018-10-10 Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003190A MX2022003190A (es) 2016-04-10 2018-10-10 Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.

Country Status (14)

Country Link
US (2) US11278555B2 (es)
EP (1) EP3442582A1 (es)
JP (2) JP2019510807A (es)
KR (2) KR20190008206A (es)
CN (2) CN109862918A (es)
AU (2) AU2017250732B2 (es)
BR (1) BR112018070847A2 (es)
CA (1) CA3020067A1 (es)
IL (1) IL262191B2 (es)
MX (2) MX390751B (es)
RU (2) RU2747258C2 (es)
SG (1) SG11201808849TA (es)
WO (1) WO2017179053A1 (es)
ZA (1) ZA201807187B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107240B2 (en) 2014-04-04 2018-10-23 Dayco Ip Holdings, Llc Check valves and Venturi devices having the same
KR102224028B1 (ko) 2014-05-30 2021-03-05 데이코 아이피 홀딩스 엘엘시 방출기, 공압식 제어 밸브 및 선택적인 흡인기를 갖는 진공 생성 시스템
EP3723785A1 (en) * 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
KR20220100546A (ko) * 2021-01-08 2022-07-15 가톨릭대학교 산학협력단 암세포의 항암 면역치료를 위한 항체-폴리에틸렌글리콜-광감각제 접합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512093A (en) 1998-12-09 2003-04-29 Yeda Res & Dev Palladium-substituted bacteriochlorophyll derivatives and use thereof
IL133253A0 (en) * 1999-12-01 2001-04-30 Yeda Res & Dev Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them
IL152900A0 (en) * 2002-11-17 2003-06-24 Yeda Res & Dev Water-soluble bacteriochlorophyll derivatives and their pharmaceutical uses
CA2661319C (en) * 2006-08-23 2015-12-01 Yeda Research And Development Co. Ltd Conjugates of rgd peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
CN102264756B (zh) 2008-10-23 2014-08-06 斯特巴生物技术有限公司 含rgd的拟肽和其用途
CA2825599C (en) * 2011-02-01 2021-07-13 The Board Of Trustees Of The University Of Illinois 4-methyl-n-hydroxybenzamide compounds as histone deacetylase (hdac) inhibitors
TWI442945B (zh) * 2011-05-18 2014-07-01 Univ Nat Taiwan 雙效微脂體用於治療的方法
WO2014141289A1 (en) 2013-03-12 2014-09-18 Amrita Vishwa Vidyapeetham University Photo - chemo composition on the basis of microcapsules with a core -shell structure

Also Published As

Publication number Publication date
IL262191B2 (en) 2025-01-01
IL262191B1 (en) 2024-09-01
RU2747258C2 (ru) 2021-04-29
US20190125769A1 (en) 2019-05-02
BR112018070847A2 (pt) 2019-02-05
RU2021110230A (ru) 2021-05-26
WO2017179053A1 (en) 2017-10-19
KR20190008206A (ko) 2019-01-23
ZA201807187B (en) 2020-01-29
CN109862918A (zh) 2019-06-07
MX390751B (es) 2025-03-21
AU2017250732A1 (en) 2018-11-15
EP3442582A1 (en) 2019-02-20
KR20220139445A (ko) 2022-10-14
CN118304400A (zh) 2024-07-09
AU2023200591A1 (en) 2023-03-09
JP2022031823A (ja) 2022-02-22
JP2019510807A (ja) 2019-04-18
IL262191A (en) 2018-11-29
US20220202838A1 (en) 2022-06-30
RU2018139523A3 (es) 2020-07-07
MX2022003190A (es) 2022-04-11
US11278555B2 (en) 2022-03-22
RU2018139523A (ru) 2020-05-15
SG11201808849TA (en) 2018-11-29
AU2017250732B2 (en) 2022-11-10
CA3020067A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX381475B (es) Terapia de combinacion que usa irinotecan liposomal y un inhibidor de poli(adp-ribosa) polimerasa (parp) para el tratamiento del cancer.
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
BR112013027119A2 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
MX2019003134A (es) Terapia de combinacion.
MX373231B (es) Agente anticancerigeno.
MX391719B (es) Agentes de quimioembolizacion.
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
MX373187B (es) Terapia de combinación para tratar cáncer.
MX2017012982A (es) Metodos y composiciones para tratar el cancer e incrementar la inmunidad terapeutica reduciendo selectivamente los monocitos m2 inmunomoduladores.
MX392408B (es) Tratamiento de cáncer gástrico usando terapias de combinación que comprenden irinotecán liposómico oxaliplatino, 5-fluoruracilo (y leucovorina).
NZ756730A (en) Combination therapy with an anti-axl antibody-drug conjugate
MX2018004177A (es) Terapia de combinacion para el tratamiento de cancer.
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
MX2018012392A (es) Terapias de combinacion para el tratamiento de cancer que comprenden un derivado de bacterioclorofila.
PH12020551176A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
CO7101244A2 (es) Fenilimidazopirazoles sustituidos y su uso
MX2020001727A (es) Terapia de combinacion.
MX2021008972A (es) Terapia de combinacion de quelante metalico para el tratamiento del cancer.
MX2024003918A (es) Agente terapeutico que induce citotoxicidad para usarse en terapia del cancer.
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.